Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

[en] Dulaglutide is a new once-weekly glucagon-like peptide-1 receptor agonist for the management of hyperglycemia in adult patients with type 2 diabetes. It stimulates dose-dependent insulin secretion and reduces glucagon secretion, both in a glucose-dependent manner. Efficacy on blood glucose control and safety were demonstrated in the large AWARD program in type 2 diabetic patients treated with diet, metformin, dual oral therapy or insulin lispro with or without metformin, confirming findings of pilot studies in Caucasian patients and data in Japanese patients. Dulaglutide 1.5 mg once weekly was superior to metformin, sitagliptin, insulin glargine and exenatide twice daily, and non-inferior to liraglutide 1.8 mg once daily regarding the reduction in glycated hemoglobin. A modest but significant weight loss was consistently observed. Most frequent adverse events were transient and generally mild gastrointestinal disturbances. Clinical outcomes of dulaglutide will not be known until the large prospective cardiovascular outcome trial REWIND is complete.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Language :

English

Title :

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Publication date :

2016

Journal title :

Expert Review of Clinical Pharmacology

ISSN :

1751-2433

eISSN :

1751-2441

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

385-99

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 21 April 2016

Statistics

Number of views

336 (4 by ULiège)

Number of downloads

1319 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911-922.
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1): S14-80
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140-149. A guide to the management of hyperglycemia of T2DM, positioning GLP-1 receptor agonists as second-line and third-line therapies.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-336.
Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43-62.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59.
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-742.
Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37:2055-2062.
Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161-1172.
Potts JE, Gray LJ, Brady EM, et al. The effect of glucagonlike peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10:e0126769.
Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144-149.
Sanford M. Dulaglutide: first global approval. Drugs. 2014;74:2097-2103.
Kuritzky L, Umpierrez G, Ekoe JM, et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126:60-72.
Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49:351-359.
Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evidence. 2015;10:11-21.
Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287-296.
European Medicines Agency. Assessment report: Trulicity (dulaglutide); 2014. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Public- assessment-report/human/002825/WC500179473.pdf
Barrington P, Chien JY, Tibaldi F, et al. LY2189265, a longacting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434-438.
Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426-433.
de la Pena A, Loghin C, Cui X, et al. Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus. Diabetes. 2014;63:A251:981-P.
European Medicines Agency. Trulicity: summary of product characteristics; 2015 Available from: http://wwwe maeuropaeu/docs/en-GB/document-library/EPAR--Product-Information/human/002825/WC500179470pdf
Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260-1267.
Terauchi Y, Satoi Y, Takeuchi M, et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61:949-959.
Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.
Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149-2158.
Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418-425
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformintreated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357.
Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241-2249.
Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37:2159-2167.
Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057-2066.
Yabe D, Seino Y, Fukushima M, et al. cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.
Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1clowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900-909.
Miyagawa J, Odawara M, Takamura T, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomised phase 3 study. Diabetes Obes Metab. 2015;17:974-983.
Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, non-inferiority study. Diabetes Obes Metab. 2015;17:994-1002.
Takamura T, Miyagawa J, Odawara M, et al. Efficacy and safety of once-weekly dulaglutide versus once-daily liraglutide in Japanese patients with type 2 diabetes. Diabetes. 2015;64(Suppl 1):A285: 1111-P.
Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-124.
Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297.
Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849-858.
Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16:748-756.
Syed YY, McCormack PL. Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus. Drugs. 2015;75:1141-1152.
Tuttle KR, McKinney TD, Davidson JA, et al. The effects of once-weekly dulaglutide on kidney function in clinical trials. Diabetes. 2015;64(Suppl 1): A286:1114-P.
Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731-737.
Ferdinand KC, Sager PT, Atisso CM, et al. Once-weekly dulaglutide does not increase the risk for CV events in type 2 diabetes: a prespecified CV meta-analysis of prospectively adjudicated CV events. Diabetes. 2015;64 (Suppl 1):A289:1127-P.
Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9:1071-1079.
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19-28.
Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Curr Med Res Opin. 2015;31:1267-1270
Scheen AJ, Which incretin-based therapy for type 2 diabetes? Lancet. 2014;384:1325-1327. Comment about the AWARD-6 study comparing the efficacy of all available GLP-1 receptor agonists in metformin-treated patients with T2DM.
Scheen AJ. Pharmacokinetics and clinical use of incretinbased therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1-21.
National Institute for health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 87; 2009 [cited 2015 July 23]. Available from: https://www.nice.org.uk/guidance/cg87
Agence Nationale des Médicaments et des Produits de Santé. Stratégie médicamenteuse du controle glycémique du diabete de type 2: recommandations; 2013 [cited 2015 July 23]. Available from: http://www. has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04-reco-diabete-type-2.pdf
Jones AG, McDonald TJ, Shields BM, et al. Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2015 Aug 4. pii: dc 150258. [Epub ahead of print].
Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig. 2012;3:294-297.
Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: association of remaining beta-cell function and achievement of HbA1c target one year after initiation. J Diabetes Complications. 2015;29:1203-1210.
Grunberger G, Forst T, Fernandez Lando L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2015 Jul 14. DOI:10.1111/dme.12833. [Epub ahead of print].
Reaney M, Yu M, Lakshmanan M, et al. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17:896-903.
Henry RR, Rosenstock J, Logan D, et al. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28:393-398.
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med. 2014;370:794-797.
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008-2017.
Scheen AJ. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol. 2015;3:667-669.
Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab. 2014;40:176-185.
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288-2296.
The U.S. National Institutes of Health. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND); 2015 [cited 2015 July 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952
Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris). 2013;74:515-522.
Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34:1174-1186.
Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. 2014;74:2141-2152.
Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228-2234.
Dejgaard TF, Knop FK, Tarnow L, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open. 2015;5:e007791.
Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75:899-910.